Rational treatment options with AEDs and ketogenic diet in Landau-Kleffner syndrome: still waiting after all these years.
Antiepileptic drugs (AEDs) remain a first treatment approach in Landau-Kleffner syndrome (LKS) and related syndromes. In the current literature, only class IV evidence is available. Inclusion criteria and outcome parameters are ill-defined. Most commonly, valproate, ethosuximide, and/or benzodiazepines are used. More recent case series show that sulthiame and especially levetiracetam can be considered as effective drugs. Smaller studies also point to the ketogenic diet as a valuable treatment option in LKS.
Lagae
Lieven
L
Department of Pediatric Neurology, University Hospitals KULeuven, Herestraat 49, Leuven, Belgium. lieven.lagae@uz.kuleuven.ac.be
D000927:Anticonvulsants / Q000627:therapeutic use*; D001521:Behavior Therapy; D001569:Benzodiazepines / Q000627:therapeutic use; D002648:Child; D003131:Combined Modality Therapy; D055423:Diet, Ketogenic / Q000379:methods*; D004569:Electroencephalography / Q000706:statistics & numerical data; D004828:Epilepsies, Partial / Q000178:diet therapy* / Q000188:drug therapy*; D005013:Ethosuximide / Q000627:therapeutic use; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D018887:Landau-Kleffner Syndrome / Q000178:diet therapy* / Q000188:drug therapy*; D012890:Sleep / Q000502:physiology; D013070:Speech Therapy; D013226:Status Epilepticus / Q000178:diet therapy / Q000188:drug therapy*; D014635:Valproic Acid / Q000627:therapeutic use
D000927:Anticonvulsants; D016756:Immunoglobulins, Intravenous; D001569:Benzodiazepines; D005013:Ethosuximide; D014635:Valproic Acid